BioWorld - Friday, November 10, 2023 See today's BioWorld Home » Hey Jalousie: IPO Window Still Open, but Pricing ‘Fates’ Vary X Subscribe to BioWorld™ news services See subscription options To read ...
The latest to price its initial public offering (IPO), Fate Therapeutics Inc. garnered about $39.6 million, an amount at the low end of its already-dipped target range, selling about 6.6 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback